TTR and preeclampsia: Further neutralizing the effects of endogenous CTS, using intravenously administered Digibind, an anti-digoxin antibody, improves renal function by reducing the NKA inhibitory activity of CTS in plasma in patients with severe preeclampsia [66,67,68,69,70].